# ESM Framework Application to MHT

## How Evidence-Selective Medicine Explains MHT Guideline Persistence

This section documents how the six-level Evidence-Selective Medicine (ESM) framework explains the 23-year persistence of restrictive MHT guidelines despite contradictory evidence.

### The Six Levels Applied to MHT

**Level 1 - Methodological Asymmetry**: 
- WHI receives minimal scrutiny despite major flaws
- Modern evidence receives heightened scrutiny despite stronger methodology

**Level 2 - Reporting Asymmetry**: 
- WHI breast cancer finding reported as definitive harm despite statistical nonsignificance
- Contradictory findings relegated to appendices

**Level 3 - Category Error**: 
- WHI findings extrapolated to all formulations despite pharmacological differences

**Level 4 - Semantic Obfuscation**: 
- "Progestin" collapses bioidentical progesterone and synthetic progestins with opposite effects

**Level 5 - Institutional Commitment Architecture**: 
- Organizations maintain restrictive guidelines to avoid acknowledging decades of failure

**Level 6 - Ethical Compartmentalization**: 
- Informed consent principles endorsed but not applied to MHT

---

## Geographic Divergence Demonstrates Institutional Selectivity

### European Guidelines (Evidence-Responsive)
- International Menopause Society (2016): Rejects "lowest dose, shortest duration"
- **All cite DOPS cardiovascular benefits**

### U.S. Guidelines (Institutionally Entrenched)
- ACOG, NAMS, Endocrine Society: Maintain restrictions
- **None cite DOPS despite 2012 publication**

**Conclusion**: Divergence reflects institutional mechanisms, not interpretive variation

---

## Real-Time Documentation: November 2025 FDA Reversal

**Prediction**: Organizations will prioritize institutional protection

**Observation**: As of December 2025, no guideline reviews announced

**This validates the ESM framework's explanatory power.**

---

## Full Framework

For complete ESM documentation: 
**[Evidence-Selective Medicine Repository](https://github.com/dolomuse/evidence-selective-medicine)**

For detailed MHT application: 
**[Part III of Full Article](../full-article/)**

---

[‚Üê Back to main repository](../)
```


```
Creative Commons Attribution 4.0 International License (CC BY 4.0)

Copyright (c) 2025 Dolores Catherino

You are free to:
- Share: copy and redistribute the material in any medium or format
- Adapt: remix, transform, and build upon the material for any purpose, even commercially

Under the following terms:
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Full license text: https://creativecommons.org/licenses/by/4.0/legalcode
